30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

1Q14 Revenue: aap Implantate

€6.1MM (~US $8.4MM), +33%

  • Trauma/LOQTEQ ~$3MM, +47% (LOQTEQ ~$1.5MM, +175%)
  • Biomaterials ~$5.3MM, +25%

Results exclude divestiture of EMCM.

  • Strong growth in Bulgaria, Czech Republic, Italy, Spain, Turkey, Russia
  • Granted U.S. patent on silver coating anti-infection technology
  • Received CE Mark approval for complete LOQTEQ clavicular plating system